Pfizer‘s better-than-expected earnings report wasn’t enough to blow away the gloom that has settled over the stock, but shares rose on the CEO’s optimism that anticipated drug tariff’s won’t have a ...
Pfizer Is Still Struggling to Replace Its COVID Revenue. Here's What We Could See From the Pharmaceutical Giant in 2026. Keep ...
Pfizer (PFE) is reiterated as a Buy, supported by the world's largest drug pipeline and trading below intrinsic value, ...
Johnson & Johnson JNJ and Pfizer PFE are both healthcare leaders with large drug portfolios and diversified revenue streams, making them direct peers in the blue-chip healthcare space. Both companies ...
Pfizer's Q3 earnings fell, but the company still raised its full-year earnings guidance. Major cost reductions remain on track, which should significantly boost the drugmaker's bottom line. Pfizer's ...
The US is preparing to exempt UK-made pharmaceuticals, ingredients and medical technology from new tariffs. The government ...
Pharmaceutical Technology on MSN
Pfizer gains another obesity asset with $2bn deal for YaoPharma’s GLP-1RA
This comes just under a month after Pfizer finalised a deal to acquire Metsera following a bidding war with Novo Nordisk.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback